molar pregnancy Archives - Revista Brasileira de Ginecologia e Obstetrícia
, , , , , Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2022;44(8):746-754
, , , , , , , , , , There are few multinational studies on gestational trophoblastic neoplasia (GTN) treatment outcomes in South America. The purpose of this study was to assess the clinical presentation, treatment outcomes, and factors associated with chemoresistance in low-risk postmolar GTN treated with first-line single-agent chemotherapy in three South American centers.
Multicentric, historical cohort study including women with International Federation of Gynecology and Obstetrics (FIGO)-staged low-risk postmolar GTN attending centers in Argentina, Brazil, and Colombia between 1990 and 2014. Data were obtained on patient characteristics, disease presentation, and treatment response. Logistic regression was used to assess the relationship between clinical factors and resistance to first-line single-agent treatment. A multivariate analysis of the clinical factors significant in univariate analysis was performed.
A total of 163 women with low-risk GTN were included in the analysis. The overall rate of complete response to first-line chemotherapy was 80% (130/163). The rates of complete response to methotrexate or actinomycin-D as first-line treatment, and actinomycin-D as second-line treatment postmethotrexate failure were 79% (125/157), 83% (⅚), and 70% (23/33), respectively. Switching to second-line treatment due to chemoresistance occurred in 20.2% of cases (33/163). The multivariate analysis demonstrated that patients with a 5 to 6 FIGO risk score were 4.2-fold more likely to develop resistance to first-line single-agent treatment (p= 0.019).
1) At presentation, most women showed clinical characteristics favorable to a good outcome, 2) the overall rate of sustained complete remission after first-line single-agent treatment was comparable to that observed in developed countries, 3) a FIGO risk score of 5 or 6 is associated with development of resistance to first-line single-agent chemotherapy.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2022;44(8):746-754
, , , , , , , , , , There are few multinational studies on gestational trophoblastic neoplasia (GTN) treatment outcomes in South America. The purpose of this study was to assess the clinical presentation, treatment outcomes, and factors associated with chemoresistance in low-risk postmolar GTN treated with first-line single-agent chemotherapy in three South American centers.
Multicentric, historical cohort study including women with International Federation of Gynecology and Obstetrics (FIGO)-staged low-risk postmolar GTN attending centers in Argentina, Brazil, and Colombia between 1990 and 2014. Data were obtained on patient characteristics, disease presentation, and treatment response. Logistic regression was used to assess the relationship between clinical factors and resistance to first-line single-agent treatment. A multivariate analysis of the clinical factors significant in univariate analysis was performed.
A total of 163 women with low-risk GTN were included in the analysis. The overall rate of complete response to first-line chemotherapy was 80% (130/163). The rates of complete response to methotrexate or actinomycin-D as first-line treatment, and actinomycin-D as second-line treatment postmethotrexate failure were 79% (125/157), 83% (⅚), and 70% (23/33), respectively. Switching to second-line treatment due to chemoresistance occurred in 20.2% of cases (33/163). The multivariate analysis demonstrated that patients with a 5 to 6 FIGO risk score were 4.2-fold more likely to develop resistance to first-line single-agent treatment (p= 0.019).
1) At presentation, most women showed clinical characteristics favorable to a good outcome, 2) the overall rate of sustained complete remission after first-line single-agent treatment was comparable to that observed in developed countries, 3) a FIGO risk score of 5 or 6 is associated with development of resistance to first-line single-agent chemotherapy.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2003;25(1):61-66
DOI 10.1590/S0100-72032003000100009
PURPOSE: to study the frequency of recurrent gestational trophoblastic neoplasm and to analyze whether the features and the outcome of the repetitive disease lead to a higher risk of invasion or of malignization and the need for more courses of chemotherapy and more aggressive regimens. METHODS: twenty-nine patients with recurrent hydatidiform mole were followed up at the Santa Casa da Misericórdia Trophoblastic Disease Center (Rio de Janeiro, Brazil) between 1960 and 2001, showing an incidence of 1.28% (29/2262). The medical charts were examined to determine the patient's age, number of pregnancies, parity, clinical presentation and chemotherapy. A total of fifty-eight trophoblastic neoplasm episodes occurred in these 29 patients and all were reviewed regarding their pathology. Statistical data were determined by the chi2 test with Yates correction and analysis was performed using Epi-Info software for Windows 2000. RESULTS: invasive mole or choriocarcinoma occurred at the first event of hydatidiform mole in only one patient (1/29 - 3.44%), whereas invasion or malignization occurred in the second event in seven patients (7/29 - 24,13%) [OR: 8.9; CI 95%: 1.5 - 41; p<0.05]. CONCLUSION: recurrent molar pregnancy was associated with histological worsening and an increase in the incidence of proliferative trophoblastic sequelae in the consecutive episodes of hydatidiform mole, more frequent and aggressive chemotherapy being necessary.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2003;25(1):61-66
DOI 10.1590/S0100-72032003000100009
PURPOSE: to study the frequency of recurrent gestational trophoblastic neoplasm and to analyze whether the features and the outcome of the repetitive disease lead to a higher risk of invasion or of malignization and the need for more courses of chemotherapy and more aggressive regimens. METHODS: twenty-nine patients with recurrent hydatidiform mole were followed up at the Santa Casa da Misericórdia Trophoblastic Disease Center (Rio de Janeiro, Brazil) between 1960 and 2001, showing an incidence of 1.28% (29/2262). The medical charts were examined to determine the patient's age, number of pregnancies, parity, clinical presentation and chemotherapy. A total of fifty-eight trophoblastic neoplasm episodes occurred in these 29 patients and all were reviewed regarding their pathology. Statistical data were determined by the chi2 test with Yates correction and analysis was performed using Epi-Info software for Windows 2000. RESULTS: invasive mole or choriocarcinoma occurred at the first event of hydatidiform mole in only one patient (1/29 - 3.44%), whereas invasion or malignization occurred in the second event in seven patients (7/29 - 24,13%) [OR: 8.9; CI 95%: 1.5 - 41; p<0.05]. CONCLUSION: recurrent molar pregnancy was associated with histological worsening and an increase in the incidence of proliferative trophoblastic sequelae in the consecutive episodes of hydatidiform mole, more frequent and aggressive chemotherapy being necessary.